Cosmos Health (NASDAQ:COSM) CFO Georgios Terzis Purchases 168,135 Shares

Cosmos Health Inc. (NASDAQ:COSM) CFO Georgios Terzis bought 168,135 shares of the stock in a transaction on Tuesday, June 16th. The shares were bought at an average cost of $0.25 per share, with a total value of $42,033.75. Following the purchase, the chief financial officer owned 2,235,398 shares of the company’s stock, valued at $558,849.50. This trade represents a 8.13% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cosmos Health Trading Up 6.9%

COSM stock traded up $0.02 during mid-day trading on Wednesday, hitting $0.27. 15,822,733 shares of the company were exchanged, compared to its average volume of 2,791,739. The company has a quick ratio of 0.92, a current ratio of 1.08 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $16.57 million, a P/E ratio of -0.41 and a beta of 4.80. The business has a fifty day simple moving average of $0.30 and a 200-day simple moving average of $0.39. Cosmos Health Inc. has a 12-month low of $0.19 and a 12-month high of $1.32.

Cosmos Health (NASDAQ:COSM) last announced its earnings results on Thursday, May 21st. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of $18.40 million during the quarter, compared to analyst estimates of $17.93 million. Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. On average, equities research analysts predict that Cosmos Health Inc. will post -0.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cosmos Health in a research note on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Trading of Cosmos Health

Several hedge funds have recently made changes to their positions in the business. XTX Topco Ltd lifted its position in shares of Cosmos Health by 52.1% during the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after purchasing an additional 34,117 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Cosmos Health by 16.7% during the first quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock worth $124,000 after purchasing an additional 55,925 shares in the last quarter. Finally, Citadel Advisors LLC lifted its position in shares of Cosmos Health by 133.1% during the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after purchasing an additional 128,776 shares in the last quarter. Institutional investors and hedge funds own 12.61% of the company’s stock.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.